Thiotepa
| Authors | |
|---|---|
| Year of publication | 2011 |
| Type | Article in Periodical |
| Magazine / Source | Farmakoterapie |
| MU Faculty or unit | |
| Citation | |
| Field | Pharmacology and pharmaceutical chemistry |
| Keywords | thiotepa; haematological malignancies; CNS tumours; autologous and allogeneic haematopoietic progenitor cell transplantation |
| Description | Thiotepa (N, N‘, N‘‘-triethylenethiophosphoramide) is an alkylating agent used in the therapy of haematological disorders of both adults (lymphomas, multiple myeloma) and children (lymphomas, leukaemias, thalassaemia, sickle cell anaemia) where it is a component of high-dosed chemotherapy regimens with subsequent autologous or allogeneic haematopoietic progenitor cell transplantation. It is also used in the therapy of CNS tumours in both children and adults, and less frequently in the therapy of other solid tumours in adults (ovarian cancer). The administration of thiotepa may be accompanied by arrhythmias, liver and kidney function disturbances (hemorrhagic cystitis), myelotoxicity, neurotoxicity, skin, gastrointestinal and reproduction toxicity, as well as the risk of secondary malignancies. Its administration should be therefore accompanied by careful monitoring such that possibly occurring undesirable effects are detected and therapeutically managed on time. |